Titan Pharmaceuticals Completes Merger with Black Titan; Shares to Begin Trading Under New Entity on Nasdaq

Reuters

2025/10/02

Titan Pharmaceuticals Completes Merger with Black Titan; Shares to Begin Trading Under New Entity on Nasdaq

Titan Pharmaceuticals Inc. has completed its previously announced business combination with Black Titan Corporation, according to a company filing. The transaction, finalized on October 1, 2025, saw Titan Pharmaceuticals merge with a wholly owned subsidiary of Black Titan, making Titan a direct subsidiary of the Cayman Islands-based company. As part of the agreement, shares of Titan Pharmaceuticals were converted into ordinary shares of Black Titan. In a related move, shareholders of TalenTec Sdn. Bhd. exchanged their shares for Black Titan ordinary shares. Following the completion of the merger, Titan Pharmaceuticals' common stock is expected to cease trading on the Nasdaq Capital Market, with Black Titan's ordinary shares set to begin trading on October 2, 2025. The company also announced changes to its board, with the resignation of Titan's directors and officers and the appointment of Chay Weei Jye as sole director and acting secretary.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Titan Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-007823), on October 01, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572935557"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572935557\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572935557?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 04:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572935557","market":"us","top_or_hot":-1,"title":"Titan Pharmaceuticals Completes Merger with Black Titan; Shares to Begin Trading Under New Entity on Nasdaq","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Titan Pharmaceuticals Completes Merger with Black Titan; Shares to Begin Trading Under New Entity on Nasdaq\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Titan Pharmaceuticals Inc. has completed its previously announced business combination with Black Titan Corporation, according to a company filing. The transaction, finalized on October 1, 2025, saw Titan Pharmaceuticals merge with a wholly owned subsidiary of Black Titan, making Titan a direct subsidiary of the Cayman Islands-based company. As part of the agreement, shares of Titan Pharmaceuticals were converted into ordinary shares of Black Titan. In a related move, shareholders of TalenTec Sdn. Bhd. exchanged their shares for Black Titan ordinary shares. Following the completion of the merger, Titan Pharmaceuticals' common stock is expected to cease trading on the Nasdaq Capital Market, with Black Titan's ordinary shares set to begin trading on October 2, 2025. The company also announced changes to its board, with the resignation of Titan's directors and officers and the appointment of Chay Weei Jye as sole director and acting secretary.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Titan Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-007823), on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Titan Pharmaceuticals Completes Merger with Black Titan; Shares to Begin Trading Under New Entity on Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTitan Pharmaceuticals Completes Merger with Black Titan; Shares to Begin Trading Under New Entity on Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-02 04:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Titan Pharmaceuticals Completes Merger with Black Titan; Shares to Begin Trading Under New Entity on Nasdaq\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Titan Pharmaceuticals Inc. has completed its previously announced business combination with Black Titan Corporation, according to a company filing. The transaction, finalized on October 1, 2025, saw Titan Pharmaceuticals merge with a wholly owned subsidiary of Black Titan, making Titan a direct subsidiary of the Cayman Islands-based company. As part of the agreement, shares of Titan Pharmaceuticals were converted into ordinary shares of Black Titan. In a related move, shareholders of TalenTec Sdn. Bhd. exchanged their shares for Black Titan ordinary shares. Following the completion of the merger, Titan Pharmaceuticals' common stock is expected to cease trading on the Nasdaq Capital Market, with Black Titan's ordinary shares set to begin trading on October 2, 2025. The company also announced changes to its board, with the resignation of Titan's directors and officers and the appointment of Chay Weei Jye as sole director and acting secretary.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Titan Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-007823), on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL3qy789:1","article_id":"2572935557","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572935557","pubTimestamp":1759350063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Titan Pharmaceuticals Inc. has completed its previously announced business combination with Black Titan Corporation, according to a company filing. The transaction, finalized on October 1, 2025, saw Titan Pharmaceuticals merge with a wholly owned subsidiary of Black Titan, making Titan a direct subsidiary of the Cayman Islands-based company. As part of the agreement, shares of Titan Pharmaceuticals were converted into ordinary shares of Black Titan. In a related move, shareholders of TalenTec Sdn. Bhd. exchanged their shares for Black Titan ordinary shares. Following the completion of the merger, Titan Pharmaceuticals' common stock is expected to cease trading on the Nasdaq Capital Market, with Black Titan's ordinary shares set to begin trading on October 2, 2025. The company also announced changes to its board, with the resignation of Titan's directors and officers and the appointment of Chay Weei Jye as sole director and acting secretary.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BTTC":"Black TITAN Corp"},"translate_title":"泰坦制药完成与黑泰坦的合并；股票将在纳斯达克新实体下开始交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BTTC":0.9,"TTNP":0.9},"content_text":"Titan Pharmaceuticals Completes Merger with Black Titan; Shares to Begin Trading Under New Entity on Nasdaq\n    \n\n        Titan Pharmaceuticals Inc. has completed its previously announced business combination with Black Titan Corporation, according to a company filing. The transaction, finalized on October 1, 2025, saw Titan Pharmaceuticals merge with a wholly owned subsidiary of Black Titan, making Titan a direct subsidiary of the Cayman Islands-based company. As part of the agreement, shares of Titan Pharmaceuticals were converted into ordinary shares of Black Titan. In a related move, shareholders of TalenTec Sdn. Bhd. exchanged their shares for Black Titan ordinary shares. Following the completion of the merger, Titan Pharmaceuticals' common stock is expected to cease trading on the Nasdaq Capital Market, with Black Titan's ordinary shares set to begin trading on October 2, 2025. The company also announced changes to its board, with the resignation of Titan's directors and officers and the appointment of Chay Weei Jye as sole director and acting secretary.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Titan Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-007823), on October 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}